(Hypertension. 1996;28:397-402.)
© 1996 American Heart Association, Inc.
Articles |
the Department of Pharmacology, Christian-Albrechts University Kiel, German Institute for High Blood Pressure Research, Heidelberg (P.G., T.U.), and Hoechst AG Frankfurt (W.L., B.A.S., G.W.) (Germany).
Correspondence to Peter Gohlke, PhD, Department of Pharmacology, Christian Albrechts University Kiel, Hospitalstr. 4, 25601 Kiel, FRG.
In previous studies in stroke-prone spontaneously hypertensive rats (SHRSP), we demonstrated that early-onset, long-term angiotensin-converting enzyme inhibitor treatment improved cardiac function and metabolism and increased aortic cGMP content even at sub-antihypertensive doses. These effects could be prevented by bradykinin type 2 (B2) receptor blockade with icatibant. In the present study, we studied the effects of long-term oral treatment with the angiotensin type 1 (AT1) receptor antagonist losartan (30 mg/kg per day) on functional and biochemical parameters of the heart and on cGMP content in the aorta in SHRSP treated prenatally and subsequently up to the age of 20 weeks. Losartan prevented the development of hypertension and left ventricular hypertrophy. Cardiac function measured ex vivo in isolated perfused hearts was improved, as demonstrated by significant increases in left ventricular pressure (22.4%), differentiated left ventricular pressure (dP/dtmax) (35.1%), and coronary flow (38%). The release of the intracellular enzymes lactate dehydrogenase and creatine kinase and of lactate into the coronary effluent was reduced by 46.4%, 47.2%, and 63.6%, respectively. In myocardial tissue, the concentrations of glycogen and the energy-rich phosphates ATP and creatine phosphate were increased by 43.2%, 33.1%, and 42.4%, respectively, whereas lactate was decreased by 57.0%. The aortic tissue content of cGMP was increased fivefold. Our results demonstrate that chronic blockade of AT1 receptors with losartan improved cardiac function and metabolism and increased aortic cGMP content in SHRSP to an extent similar to that observed previously after long-term angiotensin-converting enzyme inhibitor treatment at a comparably antihypertensive dose. Prevention of hypertension and cardiac hypertrophy as well as stimulation of non-AT1 receptors are discussed to explain the cardiac and vascular actions of losartan.
Key Words: angiotensin-converting enzyme inhibitors heart rat, stroke-prone SHR losartan receptors, angiotensin cyclic GMP
This article has been cited by other articles:
![]() |
W. D. Comper, L. M. Hilliard, D. J. Nikolic-Paterson, and L. M. Russo Disease-dependent mechanisms of albuminuria Am J Physiol Renal Physiol, December 1, 2008; 295(6): F1589 - F1600. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Forder, D. H. Munzenmaier, and A. S. Greene Angiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the rat Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1989 - H1996. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Somoza, M. C. Gonzalez, J. M. Gonzalez, F. Abderrahim, S. M. Arribas, and M. S. Fernandez-Alfonso Modulatory role of the adventitia on noradrenaline and angiotensin II responses: Role of endothelium and AT2 receptors Cardiovasc Res, February 1, 2005; 65(2): 478 - 486. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Kalinowski, T. Matys, E. Chabielska, W. Buczko, and T. Malinski Angiotensin II AT1 Receptor Antagonists Inhibit Platelet Adhesion and Aggregation by Nitric Oxide Release Hypertension, October 1, 2002; 40(4): 521 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Uhlenius, O. Vuolteenaho, and I. Tikkanen Renin-angiotensin blockade improves renal cGMP production via non-AT2-receptor mediated mechanisms in hypertension-induced by chronic NOS inhibition in rat Journal of Renin-Angiotensin-Aldosterone System, December 1, 2001; 2(4): 233 - 239. [Abstract] [PDF] |
||||
![]() |
P. Gohlke, S. Weiss, A. Jansen, W. Wienen, J. Stangier, W. Rascher, J. Culman, and T. Unger AT1 Receptor Antagonist Telmisartan Administered Peripherally Inhibits Central Responses to Angiotensin II in Conscious Rats J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 62 - 70. [Abstract] [Full Text] |
||||
![]() |
Y.-p. Sun, B.-q. Zhu, A. E. M. Browne, S. Pulukurthy, T. M. Chou, K. Sudhir, S. A. Glantz, P. C. Deedwania, K. Chatterjee, and W. W. Parmley Comparative Effects of ACE Inhibitors and an Angiotensin Receptor Blocker on Atherosclerosis and Vascular Function Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2001; 6(2): 175 - 181. [Abstract] [PDF] |
||||
![]() |
R. Bravo, B. Somoza, M. Ruiz-Gayo, C. Gonzalez, L. M. Ruilope, and M. S. Fernandez-Alfonso Differential Effect of Chronic Antihypertensive Treatment on Vascular Smooth Muscle Cell Phenotype in Spontaneously Hypertensive Rats Hypertension, May 1, 2001; e10(5): . [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Takeda, T. Yoneda, M. Demura, I. Miyamori, and H. Mabuchi Cardiac Aldosterone Production in Genetically Hypertensive Rats Hypertension, October 1, 2000; 36(4): 495 - 500. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Linz, H. Heitsch, B. A. Scholkens, and G. Wiemer Long-Term Angiotensin II Type 1 Receptor Blockade With Fonsartan Doubles Lifespan of Hypertensive Rats Hypertension, April 1, 2000; 35(4): 908 - 913. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Makino, M. Sugano, S. Ohtsuka, S. Sawada, and T. Hata Chronic antisense therapy for angiotensinogen on cardiac hypertrophy in spontaneously hypertensive rats Cardiovasc Res, December 1, 1999; 44(3): 543 - 548. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Rizzoni, E. Porteri, A. Piccoli, M. Castellano, G. Bettoni, M. L. Muiesan, G. Pasini, D. Guelfi, M. J. Mulvany, and E. A. Rosei Effects of Losartan and Enalapril on Small Artery Structure in Hypertensive Rats Hypertension, August 1, 1998; 32(2): 305 - 310. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Gohlke, C. Pees, and T. Unger AT2 Receptor Stimulation Increases Aortic Cyclic GMP in SHRSP by a Kinin-Dependent Mechanism Hypertension, January 1, 1998; 31(1): 349 - 355. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Gohlke, I. Kuwer, A. Schnell, K. Amann, G. Mall, and T. Unger Blockade of Bradykinin B2 Receptors Prevents the Increase in Capillary Density Induced by Chronic Angiotensin-Converting Enzyme Inhibitor Treatment in Stroke-Prone Spontaneously Hypertensive Rats Hypertension, January 1, 1997; 29(1): 478 - 482. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |